Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: Improved outcomes with stringent enrollment criteria - Abstract

Glickman Urololgical and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.

To analyze the acceptance rate and durability of surveillance among contemporary men with low-risk prostate cancer managed at a large, US academic institution.

Patients with low-risk parameters on initial and repeat biopsy were offered surveillance regardless of age. Regular clinical evaluation and repeat prostate biopsy were recommended every 1-2 years, and intervention was recommended based on adverse clinical and pathologic parameters on follow-up. Acceptance rate of active surveillance, freedom from intervention, and freedom from recommended intervention were measured.

Of 202 low-risk patients, 86 (43%) chose immediate treatment and 116 (57%) underwent repeat biopsy for consideration of surveillance. Intervention was recommended after initial repeat biopsy in 27 (23%) men because of higher-risk features, leaving a total of 89 men on surveillance. Over a median follow-up of 33 months, 16 men were ultimately treated and 8 were recommended to undergo treatment because of adverse clinical features on subsequent evaluations. Of the men on surveillance, the 3-year freedom from intervention and freedom from recommended intervention was 87% (95% CI, 78-93) and 93% (95% CI, 85-97), respectively.

Acceptance of surveillance (57%) in low-risk patients in this series is substantially higher than previous reports, and approximately one-third of these patients are ultimately managed by surveillance using stringent criteria. The risk of reclassification to a more aggressive cancer over short-term follow-up in appropriately selected patients is low.

Written by:
Miocinovic R, Jones JS, Pujara AC, Klein EA, Stephenson AJ.   Are you the author?

Reference: Urology. 2011 Jan 20. Epub ahead of print.
doi: 10.1016/j.urology.2010.09.063

PubMed Abstract
PMID: 21256549

UroToday.com Prostate Cancer Section

email news signup